Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PMVP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPMV Pharmaceuticals reports Q1 2026 financial results
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing first quarter 2026 financial results for period ended March 31, 2026. Specific financial figures are contained in the attached exhibit rather than the 8-K body.
Item 2.02 verify on EDGAR →
Summary
PMV Pharmaceuticals filed an 8-K on May 12, 2026 to announce its first quarter 2026 financial results. This is a routine quarterly earnings disclosure that biotech companies are expected to make. The actual financial figures and operational updates are contained in the attached press release rather than in the 8-K filing itself.
For retail investors, this represents a standard quarterly checkpoint to assess the company's cash position, research progress, and runway. The filing itself is procedural, but the attached press release likely contains material information about clinical trial progress, cash burn rate, and guidance that warrant review.
Investors should review the full press release exhibit for specific financial metrics, any updates on the company's PC14 program development, and management commentary on upcoming milestones. Watch for the company's cash position and estimated runway in the press release details.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
PMV Pharmaceuticals announced Q1 2026 financial results via press release on May 12, 2026.
Added in current filing · verify on EDGAR →
On May 12, 2026, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, which are provided in the attached press release exhibit. This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
PMV Pharmaceuticals filed an 8-K attaching a press release dated May 12, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release issued by PMV Pharmaceuticals, Inc., dated May 12, 2026.
The 8-K references an attached press release dated May 12, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the press release content, so the nature and materiality of the announcement cannot be determined from this 8-K text alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify